Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis

NA Nuñez, B Joseph, M Pahwa, R Kumar… - Journal of affective …, 2022 - Elsevier
Objective To compare the efficacy and discontinuation of augmentation agents in adult
patients with treatment-resistant depression (TRD). We conducted a systematic review and …

Pharmacotherapies for treatment-resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape

MK Jha, SJ Mathew - American Journal of Psychiatry, 2023 - Am Psychiatric Assoc
One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

RS McIntyre, M Alsuwaidan, BT Baune, M Berk… - World …, 2023 - Wiley Online Library
Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis

BDM Jones, LB Razza, CR Weissman, J Karbi… - JAMA network …, 2021 - jamanetwork.com
Importance The placebo effect in depression clinical trials is a substantial factor associated
with failure to establish efficacy of novel and repurposed treatments. However, the …

Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium

GH Vázquez, A Bahji, J Undurraga… - Journal of …, 2021 - journals.sagepub.com
Background: Successful treatment of major depressive disorder (MDD) can be challenging,
and failures (" treatment-resistant depression"[TRD]) are frequent. Steps to address TRD …

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study

WR Earley, MV Burgess, B Khan, L Rekeda… - Bipolar …, 2020 - Wiley Online Library
Objective To assess the efficacy, safety, and tolerability of cariprazine in the treatment of the
depressed phase of bipolar I disorder in adults (NCT02670538). Methods In this phase 3 …

Dopamine receptor partial agonists: Do they differ in their clinical efficacy?

P Mohr, J Masopust, M Kopeček - Frontiers in Psychiatry, 2022 - frontiersin.org
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine)
constitute a novel class of antipsychotics. Although they share a similar mechanism of …

Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study

GS Sachs, PP Yeung, L Rekeda… - American Journal of …, 2023 - Am Psychiatric Assoc
Objective: The purpose of this study was to investigate the efficacy of cariprazine, a
dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist, as adjunctive …

Pharmacological interventions for treatment‐resistant depression in adults

P Davies, S Ijaz, D Kessler, G Lewis… - Cochrane Database of …, 2019 - cochranelibrary.com
Background Although antidepressants are often a first‐line treatment for adults with
moderate to severe depression, many people do not respond adequately to medication, and …

Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data

SM Stahl, S Laredo… - Therapeutic Advances in …, 2020 - journals.sagepub.com
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as
'atypical'second generation antipsychotics. Originally approved for acute and maintenance …